EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

G3BP2 confers venetoclax resistance by stabilizing ELF1-mediated MCL1 transcription in acute myeloid leukemia

Zhixiang Chen, Yuanhua Cai, Yaping Wang, Xiaolin Lai, Xiongbin Yan, Xuechun Wang, Fuquan Tu, Wanting Wu, Huiyin Gao, Yi Zheng, Yingying Zeng, Yang Li und 6 weitere

Leukemia · 2026

DOI: 10.1038/s41375-026-03063-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Leukemia, 2026. Verfasst von Zhixiang Chen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, F…. Hauptthemen laut MEDLINE: Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides, Myeloid Cell Leukemia Sequence 1 Protein, Leukemia, Myeloid, Acute. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China (National Science Foundation of China), Natural Science Foundation of Fujian Province (Fujian Provincial Natural Science Foundation).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Venetoclax is a promising treatment for acute myeloid leukemia (AML) patients, but resistance occurs following the upregulation of MCL1. The RNA-binding protein G3BP2 is upregulated in various solid tumors, and targeting G3BP2 has been shown to restore chemosensitivity. However, the role of G3BP2 in AML development and venetoclax resistance remains unknown. Herein, an integrated analysis revealed that G3BP2 confers venetoclax resistance and correlates with poor outcomes in AML. G3BP2 deficiency inhibits AML proliferation and induces apoptosis in AML cells and xenograft mice. G3BP2 expression aligns with MCL1 levels across AML cohorts, and the regulatory effect of G3BP2 on MCL1 was validated in AML cells. Notably, G3BP2 and MCL1 do not interact directly; instead, G3BP2 interacts with ELF1 mRNA to increase its stability. The transcription factor ELF1 binds to the MCL1 promoter to induce its expression, which can be attenuated by G3BP2 inhibition. Furthermore, C108-mediated inhibition of G3BP2, in combination with venetoclax, has anticancer effects in primary AML cells and in patient-derived xenografts (PDX). C108 increases the therapeutic efficacy of venetoclax and their combination prolongs overall survival (OS) in AML model mice. These findings identify G3BP2 as a regulator of venetoclax resistance through ELF1-mediated MCL1 transcription, suggesting new therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bridged Bicyclo Compounds, HeterocyclicSulfonamidesMyeloid Cell Leukemia Sequence 1 ProteinLeukemia, Myeloid, AcuteDrug Resistance, NeoplasmRNA-Binding ProteinsTranscription FactorsHumansAnimalsMiceXenograft Model Antitumor AssaysApoptosisAntineoplastic AgentsTranscription, GeneticCell Line, TumorCell Proliferation

Substanzen

Bridged Bicyclo Compounds, HeterocyclicvenetoclaxSulfonamidesMyeloid Cell Leukemia Sequence 1 ProteinMCL1 protein, humanRNA-Binding ProteinsTranscription FactorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
  • Union Clinical Medical Colleges, Fujian Medical University, Fuzhou, China.
  • Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China. shaoyuanwang@fjmu.edu.cn.
  • Union Clinical Medical Colleges, Fujian Medical University, Fuzhou, China. shaoyuanwang@fjmu.edu.cn.

Förderung

  • National Natural Science Foundation of China (National Science Foundation of China)
  • Natural Science Foundation of Fujian Province (Fujian Provincial Natural Science Foundation)

Zitieren

APA

Chen, Z., Cai, Y., Wang, Y., Lai, X., Yan, X., Wang, X., Tu, F., Wu, W., Gao, H., Zheng, Y., Zeng, Y., Li, Y., Li, J., Pan, L., Wang, P., Ji, W., Xu, L., & Wang, S. (2026). G3BP2 confers venetoclax resistance by stabilizing ELF1-mediated MCL1 transcription in acute myeloid leukemia. Leukemia. https://doi.org/10.1038/s41375-026-03063-5

Vancouver

Chen Z, Cai Y, Wang Y, Lai X, Yan X, Wang X, et al. G3BP2 confers venetoclax resistance by stabilizing ELF1-mediated MCL1 transcription in acute myeloid leukemia. Leukemia. 2026. doi:10.1038/s41375-026-03063-5

BibTeX
@article{Chen2026,
  author = {Chen, Zhixiang and Cai, Yuanhua and Wang, Yaping and Lai, Xiaolin and Yan, Xiongbin and Wang, Xuechun and Tu, Fuquan and Wu, Wanting and Gao, Huiyin and Zheng, Yi and Zeng, Yingying and Li, Yang and Li, Jinggang and Pan, Lili and Wang, Peiyao and Ji, Wei and Xu, Lin and Wang, Shaoyuan},
  title = {G3BP2 confers venetoclax resistance by stabilizing ELF1-mediated MCL1 transcription in acute myeloid leukemia},
  journal = {Leukemia},
  year = {2026},
  doi = {10.1038/s41375-026-03063-5}
}
Kostenlos starten →